Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Non-GAAP combined R&D, AIPR&D and SG&A expenses by Year
Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M) ($M)
Vertex Pharmaceuticals Non-GAAP combined R&D, AIPR&D and SG&A expenses: $5,118M in FY2025, down 42.0% from a year earlier.
Where the FY2025 figure comes from
“|| Combined non-GAAP R&D, AIPR&D and SG&A expenses | $ | 1,362.1 | $ | 1,297.4 | $ | 5,118.2 | $ | 8,821.7”
Source: Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗
Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 5,118 | -42.0% | Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗ |
| FY2024 | Dec 31, 2024 | 8,822 | +137.5% | Form 8-K (ex-991_q42025.htm, filed 2026-02-12) ↗ |
| FY2023 | Dec 31, 2023 | 3,715 | – | Form 8-K (ex-991_q42024.htm, filed 2025-02-10) ↗ |
| FY2021 | Dec 31, 2021 | 2,332 | +17.7% | Form 8-K (ex-991_q42021.htm, filed 2022-01-26) ↗ |
| FY2020 | Dec 31, 2020 | 1,981 | +17.0% | Form 8-K (ex-991_q42021.htm, filed 2022-01-26) ↗ |
| FY2019 | Dec 31, 2019 | 1,694 | +10.9% | Form 8-K (ex-991_q42020.htm, filed 2021-02-01) ↗ |
| FY2018 | Dec 31, 2018 | 1,527 | +14.4% | Form 8-K (ex-991q42019.htm, filed 2020-01-30) ↗ |
| FY2017 | Dec 31, 2017 | 1,335 | +11.0% | Form 8-K (ex-991_q42018.htm, filed 2019-02-05) ↗ |
| FY2016 | Dec 31, 2016 | 1,202 | – | Form 8-K (ex-991_q42017.htm, filed 2018-01-31) ↗ |
Breakdown
What makes up non-GAAP combined R&D, AIPR&D and SG&A expenses
Cite this data
StockData. (2026). Vertex Pharmaceuticals Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M), annual FY2016–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-comb-rd-sga
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.